VONJO Sales Forecast And Market Size Analysis 2026-2034: Differentiated Treatment Position Strengthens In Severe Thrombocytopenic Myelofibrosis
VONJO (pacritinib) is an oral kinase inhibitor approved by the U.S. Food and Drug Administration for adults with intermediate- or high-risk primary or secondary myelofibrosis and platelet counts below 50 109/L. Its indication includes secondary myelofibrosis following polycythemia vera or essential thrombocythemia. By addressing severe thrombocytopenia, VONJO serves a high-risk patient population with limited treatment options and occupies a differentiated position in the myelofibrosis treatment market.
Key Factors Supporting VONJO Market Growth
- Differentiated position in severe thrombocytopenic myelofibrosis: VONJO is the first and only FDA-approved therapy specifically indicated for myelofibrosis patients with platelet counts below 50 109/L. This distinct label supports adoption among hematologists treating patients for whom other JAK inhibitors may be difficult to use because of cytopenias. Phase III clinical evidence: FDA approval was supported by the Phase III PERSIST-2 trial. Among patients with platelet counts below 50 109/L, 29% of pacritinib-treated patients achieved at least a 35% reduction in spleen volume, compared with 3% of patients receiving best available therapy. Clinically meaningful symptom improvement was also reported. Guideline recognition: National Comprehensive Cancer Network guidelines identify pacritinib as a preferred treatment option for patients with severe thrombocytopenia. Recommendations also cover selected patients with higher platelet counts following prior JAK inhibitor treatment and recognize its potential relevance in myelofibrosis-associated anemia. Differentiated pharmacologic profile: VONJO inhibits JAK2, IRAK1 and ACVR1 while largely sparing JAK1. Its activity across these pathways continues to generate clinical interest, particularly for patients affected by thrombocytopenia and anemia. Commercial adoption: More than 1,000 patients received commercial treatment with VONJO during 2022, generating approximately US$54 million in net sales during the first nine months following launch. Continued penetration of the approved population and selected broader platelet-count subgroups could support future growth.
The PACIFICA confirmatory study is intended to provide additional efficacy, safety and long-term outcome data supporting the conversion of VONJO's accelerated approval to traditional FDA approval. Positive confirmatory results could reinforce physician confidence, payer coverage and commercial uptake. Based on publicly available company information and consensus estimates, rather than proprietary market research, annual global VONJO sales have generally been projected at approximately US$150 million to US$250 million over the next several years.
VONJO Clinical and Safety Profile
VONJO is administered orally twice daily and has demonstrated reductions in spleen volume and improvements in myelofibrosis-related symptoms across its clinical development program. Common adverse reactions include diarrhea, nausea, thrombocytopenia, anemia and peripheral edema. Treatment requires appropriate monitoring for bleeding, cardiac events, infections and other clinically significant risks in accordance with approved prescribing information.
Sobi Acquisition of CTI BioPharma
In May 2023, Swedish Orphan Biovitrum AB (publ), known as Sobi, announced an agreement to acquire CTI BioPharma Corp., a biopharmaceutical company focused on blood cancers and rare diseases. The transaction added VONJO to Sobi's hematology portfolio, strengthening the company's presence in myelofibrosis and supporting the product's continued commercial development. VONJO had received accelerated FDA approval in February 2022.
Scope of the VONJO Market Report
The "VONJO Sales Forecast and Market Size Analysis to 2034" report evaluates the product's historical performance, current utilization and future commercial potential across the seven major pharmaceutical markets: the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. Coverage includes approved use in myelofibrosis and potential development opportunities in graft-versus-host disease and VEXAS syndrome.
- VONJO mechanism of action, dosage, administration and clinical profile Regulatory milestones and ongoing research and development activities Historical sales, current market performance and forecasts through 2034 Pricing, reimbursement, treatment-cost estimates and regional variations Patent coverage, potential generic entry and anticipated pricing impact Clinical trials by indication, intervention, status and expected completion date Competitive analysis of marketed products and late-stage emerging therapies SWOT analysis, analyst perspectives and strategic market positioning
VONJO Competitive Landscape and Revenue Potential
The VONJO market assessment examines competition from approved myelofibrosis treatments and pipeline therapies that could influence prescribing patterns, market share and pricing. The analysis considers VONJO's clinical differentiation, positioning in severe thrombocytopenia, efficacy and safety profile, reimbursement environment, commercial partnerships and regulatory milestones.
Future performance will depend on confirmatory clinical results, physician adoption, payer access, competitive launches and potential development in additional indications. Growth opportunities include deeper penetration of the approved severe thrombocytopenia population, broader guideline-supported use and continued commercial execution across major markets. Conversely, new treatment options, regulatory uncertainty and pricing pressure may affect the VONJO sales forecast through 2034.
Key Questions Addressed
- What are VONJO's mechanism of action, administration route and clinical characteristics? How has VONJO performed clinically and commercially since FDA approval? What are the current and forecast VONJO sales across the United States, Europe and Japan? Which regulatory, clinical and commercial milestones could affect market growth? How is VONJO positioned against marketed JAK inhibitors and emerging myelofibrosis therapies? What pricing, reimbursement and regional cost factors may influence patient access? What opportunities could arise from research in graft-versus-host disease and VEXAS syndrome? Which assumptions support the VONJO market size and revenue forecast through 2034?
The report is developed using internal databases, primary and secondary research, publicly available regulatory information, company disclosures, scientific publications, industry journals, trade associations and expert analysis. Its integrated clinical, regulatory and commercial assessment is designed to support portfolio planning, competitive intelligence and strategic decision-making within the global myelofibrosis market.
Key Topics Covered
1. Report Introduction
2. VONJO Overview in approved indications like Myelofibrosis; as well as potential indication like Graft-versus-host disease and VEXAS syndrome
2.1. Product Detail
2.2. VONJO Clinical Development
2.2.1. VONJO Clinical studies
2.2.2. VONJO Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. VONJO Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging VONJO Therapies)
5. VONJO Market Assessment
5.1. VONJO Market Outlook in approved and potential indications
5.2. 7MM Analysis
5.2.1. VONJO Market Size in the 7MM for approved and potential indications
5.3. Country-wise Market Analysis
5.3.1. VONJO Market Size in the United States for approved and potential indications
5.3.2. VONJO Market Size in Germany for approved and potential indications
5.3.3. VONJO Market Size in France for approved and potential indications
5.3.4. VONJO Market Size in Italy for approved and potential indications
5.3.5. VONJO Market Size in Spain for approved and potential indications
5.3.6. VONJO Market Size in the United Kingdom for approved and potential indications
5.3.7. VONJO Market Size in Japan for approved and potential indications
6. VONJO SWOT Analysis
7. Analysts' Views
8. Appendix
8.1. Bibliography
8.2. Report Methodology
List of Tables
Table 1: VONJO, Clinical Trial Description, 2023
Table 2: VONJO, General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: VONJO's pricing and cost Assumptions
Table 6: VONJO's Sales Analysis in the 7MM, in USD million (2020-2034)
Table 7: VONJO Market Size in the US, in USD million (2020-2034)
Table 8: VONJO Market Size in Germany, in USD million (2020-2034)
Table 9: VONJO Market Size in France, in USD million (2020-2034)
Table 10: VONJO Market Size in Italy, in USD million (2020-2034)
Table 11: VONJO Market Size in Spain, in USD million (2020-2034)
Table 12: VONJO Market Size in the UK, in USD million (2020-2034)
Table 13: VONJO Market Size in Japan, in USD million (2020-2034)
List of Figures
Figure 1: VONJO's Sales Analysis in the 7MM, USD million (2020-2034)
Figure 2: VONJO Market Size in the United States, USD million (2020-2034)
Figure 3: VONJO Market Size in Germany, USD million (2020-2034)
Figure 4: VONJO Market Size in France, USD million (2020-2034)
Figure 5: VONJO Market Size in Italy, USD million (2020-2034)
Figure 6: VONJO Market Size in Spain, USD million (2020-2034)
Figure 7: VONJO Market Size in the United Kingdom, USD million (2020-2034)
Figure 8: VONJO Market Size in Japan, USD million (2020-2034)
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment